Related Experiment Videos
Pulmonary alveolar proteinosis
Jeffrey J Presneill1, Koh Nakata, Yoshikazu Inoue
1Intensive Care Unit, Royal Melbourne Hospital, Grattan Street, Parkville 3050, Victoria, Australia.
Clinics in Chest Medicine
|August 28, 2004
Summary
Pulmonary alveolar proteinosis (PAP) is a lung condition characterized by surfactant buildup. Survival rates for adult PAP patients have improved, with recent research advancing understanding of surfactant biology and immune defense.
Area of Science:
- Pulmonary Medicine
- Respiratory Biology
- Immunology
Background:
- Pulmonary alveolar proteinosis (PAP) is a rare lung disease.
- It is characterized by the accumulation of surfactant lipoprotein in the alveoli.
- This accumulation impairs pulmonary gas exchange.
Purpose of the Study:
- To review the pathophysiologic mechanisms of PAP.
- To discuss the prognosis and survival rates for adult PAP patients.
- To highlight recent advances in PAP research and pulmonary surfactant biology.
Main Methods:
- Literature review of studies on Pulmonary alveolar proteinosis.
- Analysis of pathophysiologic mechanisms and clinical outcomes.
- Synthesis of recent laboratory and clinical research findings.
Main Results:
- At least three distinct pathophysiologic mechanisms contribute to PAP.
- Disease-specific survival for adult PAP patients exceeds 80% at 5 years.
- Survival rates have shown progressive improvement over the past four decades.
Conclusions:
- Recent research has significantly advanced the understanding of PAP.
- New insights into pulmonary surfactant biology and innate immune defense are emerging.
- Improved understanding may lead to better diagnostic and therapeutic strategies for PAP.